| 1. | Diabetes mellitus - skin manifestations | 1 | |
|
| 2. | NCCT vs CECT | 0 | |
|
| 3. | Types of motility of microorganisms - part 2 | 0 | |
|
| 4. | Cardiological - Xray findings | 0 | |
|
| 5. | Biosynthesis of androgens | 1 | |
|
| 6. | Tissue stem cells and location | 0 | |
|
| 7. | Hyperkalemia - ECG changes and management | 0 | |
|
| 8. | Inheritance pattern of important diseases - part 4 | 0 | |
|
| 9. | Special lesions | 1 | |
|
| 10. | Cell to basal lamina anchoring junctions | 0 | |
|
| 11. | Organism - Transport media | 0 | |
|
| 12. | Volume of distribution - part 2 | 1 | |
|
| 13. | Joubert syndrome and schizencephaly | 0 | |
|
| 14. | Histopathology named cells - part 2 | 0 | |
|
| 15. | Layers of cerebral cortex | 0 | |
|
| 16. | Airway - Structure | 0 | |
|
| 17. | Multidrug therapy - Leprosy | 0 | |
|
| 18. | Immunoglobulin classes properties - part 1 | 1 | |
|
| 19. | Meningitis - Classic triad of symptoms | 1 | |
|
| 20. | Multiple myeloma and cells - part 1 | 0 | |
|
| 21. | BPH - Benign prostatic hyperplasia treatment | 0 | |
|
| 22. | Allergic contact dermatitis , photoallergic dermatitis - Diagnostic test | 0 | |
|
| 23. | Exocrine glands and examples | 1 | |
|
| 24. | Fetal circulation | 0 | |
|
| 25. | Drugs in therapeutic drug monitoring - part 2 | 0 | |
|
| 26. | Anti Diarrhea drugs - part 3 | 0 | |
|
| 27. | Neurons - Classification based on neuronal processes | 0 | |
|
| 28. | Shoulder joint - Spaces | 0 | |
|
| 29. | Arteriovenous fistula | 0 | |
|
| 30. | Endocrine hormones - Signalling pathways | 0 | |
|
| 31. | Structures passing through skull foramen | 0 | |
|
| 32. | Pregnancy - Safe drugs | 1 | |
|
| 33. | Multiple myeloma - Diagnostic criteria | 1 | |
|
| 34. | Lichen nitidus | 0 | |
|
| 35. | Pituitary tumors and Japanese encephalitis | 0 | |
|
| 36. | Pathological named bodies - part 1 | 1 | |
|
| 37. | Fixed dose combination | 0 | |
|
| 38. | Burkitts lymphoma - part 3 | 0 | |
|
| 39. | Dermatomyositis | 1 | |
|
| 40. | CYP 2c8 and 2c9 | 0 | |
|
| 41. | FAST - Focus assessment with sonography | 0 | |
|
| 42. | Drug elimination - Biotransformation | 1 | |
|
| 43. | Parasitic eggs - part 1 | 0 | |
|
| 44. | Eclampsia - Management protocol | 0 | |
|
| 45. | Central nervous system tumours and their histopathological findings - part 4 | 0 | |
|
| 46. | Syphilis | 1 | |
|
| 47. | Intraartrial septum | 0 | |
|
| 48. | Coarctation of aorta - Presentation | 0 | |
|
| 49. | Blood vessels - Types | 0 | |
|
| 50. | G protein coupled receptors | 0 | |
|
| 51. | Fixed drug eruption | 1 | |
|
| 52. | ADHD - Diagnosis and treatment | 0 | |
|
| 53. | Rectum - Carcinoma | 0 | |
|
| 54. | Chelating agents - Part 1 | 0 | |
|
| 55. | Barium studies | 1 | |
|
| 56. | Nephrotic vs nephritic syndrome - part 3 | 0 | |
|
| 57. | Benign prostatic hyperplasia | 0 | |
|
| 58. | Golden points : Pupil size causes | 0 | |
|
| 59. | Homologous structures - Males and females | 0 | |
|
| 60. | Golden points : Dopamine and dose effects | 1 | |
|
| 61. | Modified dukes criteria - Infective endocarditis | 1 | |
|
| 62. | Golden points : Absorbable suture materials | 0 | |
|
| 63. | Golden points : Glucose transporters - part 1 | 1 | |
|
| 64. | Lupus erythematosus types | 0 | |
|
| 65. | Tocolytics | 0 | |
|
| 66. | Gastrointestinal motility - Types | 0 | |
|
| 67. | SGLT and GLUT transporters - part 2 | 0 | |
|
| 68. | Aortic stenosis grading | 0 | |
|
| 69. | Vitamin D | 0 | |
|
| 70. | Primitive gut - Blood supply and derivatives | 0 | |
|
| 71. | Heart valves - Surface marking | 0 | |
|
| 72. | Face of giant panda sign | 0 | |
|
| 73. | Rickets - Radiological features | 1 | |
|
| 74. | Glasgow blatchford bleeding score | 0 | |
|
| 75. | Tuberous sclerosis - Radiological findings | 0 | |
|
| 76. | Lichen planus - Part 2 | 0 | |
|
| 77. | Golden points : Glycogen storage disorders part 4 | 0 | |
|
| 78. | Gonadotropin releasing hormone - Gnrh receptor antagonist | 0 | |
|
| 79. | Multiple myeloma and cells - part 2 | 1 | |
|
| 80. | Peptic ulcer disease - Common causes | 0 | |
|
| 81. | Receptor binding - part 3 | 0 | |
|
| 82. | Sacral plexus | 0 | |
|
| 83. | Nitrates - Uses and adverse effects | 1 | |
|
| 84. | CHA2DS2 - VASC scoring for risk of stroke and oral anti coagulation need in AF | 0 | |
|
| 85. | Rate of net diffusion - Factors | 0 | |
|
| 86. | Melanoma | 0 | |
|
| 87. | Hypothyroidism | 0 | |
|
| 88. | Dermatitis herpetiformis | 0 | |
|
| 89. | Beta oxidation of fatty acids | 1 | |
|
| 90. | Parasites - Definitive and Intermediate hosts | 0 | |
|
| 91. | Psoriatic nails vs oncomycosis | 0 | |
|
| 92. | H Pylori - Eradication | 0 | |
|
| 93. | Inclusion bodies - part 4 | 0 | |
|
| 94. | Golden points : ETCO2 Increase and decrease conditions | 0 | |
|
| 95. | Congenital ichthyosis | 1 | |
|
| 96. | Types of transport - Characteristics | 0 | |
|
| 97. | Seizure , epilepsy drugs | 1 | |
|
| 98. | Ependyoma, medulloblastoma and pilocytic astrocytoma | 0 | |
|
| 99. | CYP 2d6 | 0 | |
|
| 100. | Bacterial vaginosis | 0 | |
|
